FDA 483 OBSERVATION · #153 OF 1,945 MOST-CITED
Storage
FDA cited this observation 204 times across 200 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
Food, ingredients, or packaging were not stored and held under conditions that protect them against contamination and deterioration — pallets on wet floors, no pest exclusion, temperature or humidity not controlled, or raw and finished goods and allergens commingled. This is the warehousing-and-distribution requirement of §117.93.
Why FDA writes it — Improper storage lets otherwise safe food become adulterated after production through pest activity, moisture, temperature abuse, or allergen cross-contact. FDA cites this because holding conditions are part of protecting food from farm to distribution, and a lapse in the warehouse undoes upstream controls.
- Store food off the floor and away from walls on clean pallets or racking, with defined spacing that allows cleaning and inspection.
- Control storage temperature and humidity for products that require it and monitor and record those conditions.
- Segregate allergens, raw materials, chemicals, and finished goods so cross-contact and chemical contamination cannot occur.
- Apply stock rotation (FEFO/FIFO) and a warehouse pest-management and sanitation program, with records to prove conditions were maintained.
- Warehouse treated as outside the food safety scope, so storage conditions were never monitored or included in sanitation.
- Space pressure leading to overstacking, floor storage, and commingling that defeats segregation and cleaning.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.2× the rate of the average FDA-cited firm (9.5% vs 7.8%), across 200 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Labels were stored such that mix-ups were possible.
Failure to store raw materials in a manner that protects against contamination.
Failure to store raw materials in a manner that protects against contamination.
Failure to store raw materials in a manner that protects against contamination.
Failure to store raw materials in a manner that protects against contamination.
Failure to store raw materials in a manner that protects against contamination.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →